Trial · NCT03269318
PRISTINE - Personalised Approach to Improve aSThma prescrIbing iN childrEn
NCT03269318, Phase 4, Terminated, Brighton and Sussex University Hospitals NHS Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PRISTINE - Personalised Approach to Improve aSThma prescrIbing iN childrEn. Trials, record NCT03269318. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03269318
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PRISTINE - Personalised Approach to Improve aSThma prescrIbing iN childrEn
- NCT number
- NCT03269318
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 2 participants, actual
- Lead sponsor
- Brighton and Sussex University Hospitals NHS Trust
- Conditions
- Asthma
- Interventions
- Montelukast or Salmeterol or Theophylline or Steroid
- First posted
- 2017-08-31
- Last updated
- 2019-12-18
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Are children with asthma and their parents willing to be recruited and randomised to a trial of genotyping and personalised management for asthma? Qualitative interview | Baseline to 3 months | Recruitment rates will be measured as rate of invited participants who are eligible and consenting and will be reported in a Consolidated Standards of Reporting Trials (CONSORT) participant flowchart. |
| Primary | Are there retention issues? If yes, at what stages did these occur? What were the reasons? Qualitative interview | Baseline to 3 months | Acceptability of allocation procedures will be assessed by examining reasons for dropout in discontinuing participants and comparing attrition rates between the two study groups and between participants who did and did not receive their preferred allocation. Attrition rates will be established as discontinuation of intervention and loss to follow-up measurement for both groups |
| Primary | Are follow-up data complete? | Baseline to 3 months | Suitability of outcome measures will be evaluated based on completion rates and rates of missing data |
| Primary | Acceptability of personalised approach | Baseline to 3 months | All participants and their parents/guardians will be invited to have a semi-structured interview with a member of the research team in order to discuss their experiences of living with and managing their asthma. To enhance communication and ensure the child's perspective is captured, children will be invited to make a drawing of what it is like to have asthma and what it feels like when they take their asthma medication. The research team interviewing will then discuss the drawings (as a visual cue) in simple language with each child to understand what the child means. |
| Secondary | Childhood Asthma Control Test | Baseline to 3 months | The Childhood Asthma Control Test (C-ACT) \[10\], a 7-item validated questionnaire capturing the frequency of asthma symptoms and their effect on daily function in children 4 to 11 years of age. It uses a 4-point Likert scale with higher scores indicating better control. The C-ACTuses a single cut point of a score of ≤19 to identify children whose asthma is not well controlled. |
| Secondary | Lung Function | Baseline to 3 months | Lung function will be measured by a nurse trained in collecting spirometry data in the Royal Alexandra Children's Hospital. Measure of PEF (litres/second), FEV1 (litres) and FVC (litres) |
| Secondary | Days unable to complete usual activities | Baseline to 3 months | Participants and parents will be asked to report how many days in the last month they have been unable to complete usual activities as a result of their asthma. |
| Secondary | Use of medication | Baseline to 3 months | Number of courses of oral corticosteroids for asthma and any other medication use will be recorded. |
| Secondary | Use of health services | Baseline to 3 months | Participants and parents will be asked to report how many times they have had to see their GP or asthma nurse (outside of routine asthma review), been to A\&E or been admitted to hospital as a result of their asthma. |
| Secondary | Beliefs about medicine questionnaire | Baseline to 3 months | The Beliefs About Medicine Questionnaire (BMQ) \[11\] is an 18-item validated questionnaire which will capture parental beliefs about asthma, asthma medication and how these may have affected their child's life. Respondents indicate their degree of agreement with each individual statement about medicines on a 5-point Likert scale, (1=strongly disagree to 5=strongly agree). Scores obtained are summed to give a scale score with higher scores indicating stronger beliefs. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03269318
GET https://conductscience.org/api/trials/v1/NCT03269318/registered